Clinical research jobs provider Lilly has published new trial data from a study of its new therapy for erectile dysfunction (ED) and benign prostatic hyperplasia (BPH), Cialis.
Findings from the phase III trial showed that the treatment met its co-primary endpoints of providing significant improvements for males suffering from both conditions when compared with a placebo.
The study was the first to evaluate the therapy in an exclusively male patient population, with 606 participants from nine countries examined over a 12-week period.
Research findings are set to be used to support regulatory applications that Lilly has made for approval of the therapy against both conditions.
"Lilly is committed to research that can help us offer new treatment options and advance our understanding of ED and BPH, conditions that affect millions of men worldwide," commented Dr Anthony Beardsworth, the company's senior medical director.
The results come after Lilly received a recommendation from the European Medicine Agency's Committee for Medicinal Products for Human Use for its Alimta drug for use as a continuation maintenance therapy for lung cancer.